| Lipid-based formulations for intestinal lymphatic delivery CM O’Driscoll European Journal of Pharmaceutical Sciences 15 (5), 405-415, 2002 | 494 | 2002 |
| Biopharmaceutical challenges associated with drugs with low aqueous solubility—the potential impact of lipid-based formulations CM O'driscoll, BT Griffin Advanced drug delivery reviews 60 (6), 617-624, 2008 | 365 | 2008 |
| PEGylated gold nanoparticles: polymer quantification as a function of PEG lengths and nanoparticle dimensions K Rahme, L Chen, RG Hobbs, MA Morris, C O'Driscoll, JD Holmes Rsc Advances 3 (17), 6085-6094, 2013 | 359 | 2013 |
| Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories R Hayeshi, C Hilgendorf, P Artursson, P Augustijns, B Brodin, ... European Journal of Pharmaceutical Sciences 35 (5), 383-396, 2008 | 295 | 2008 |
| Gold nanoparticles enlighten the future of cancer theranostics J Guo, K Rahme, Y He, LL Li, JD Holmes, CM O’Driscoll International journal of nanomedicine, 6131-6152, 2017 | 285 | 2017 |
| Lipid-based nanocarriers for oral peptide delivery Z Niu, I Conejos-Sánchez, BT Griffin, CM O’Driscoll, MJ Alonso Advanced drug delivery reviews 106, 337-354, 2016 | 251 | 2016 |
| Life in 3D is never flat: 3D models to optimise drug delivery KA Fitzgerald, M Malhotra, CM Curtin, FJ O'Brien, CM O'Driscoll Journal of controlled release 215, 39-54, 2015 | 251 | 2015 |
| The blood-brain barrier in aging and neurodegeneration EG Knox, MR Aburto, G Clarke, JF Cryan, CM O’Driscoll Molecular Psychiatry 27 (6), 2659-2673, 2022 | 232 | 2022 |
| Pattern recognition receptors—molecular orchestrators of inflammation in inflammatory bowel disease D Walsh, J McCarthy, C O’Driscoll, S Melgar Cytokine & growth factor reviews 24 (2), 91-104, 2013 | 193 | 2013 |
| Cell transfection with polycationic cyclodextrin vectors SA Cryan, A Holohan, R Donohue, R Darcy, CM O’Driscoll European journal of pharmaceutical sciences 21 (5), 625-633, 2004 | 175 | 2004 |
| Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? J Guo, L Bourre, DM Soden, GC O'Sullivan, C O'Driscoll Biotechnology advances 29 (4), 402-417, 2011 | 148 | 2011 |
| Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models ODCM O’Neill JM, Bourre L, Melgar S Drug Discovery Today 16 (5/6), 203-218, 2011 | 141 | 2011 |
| Nanoparticles and the Blood-Brain Barrier: Advancing from In-Vitro Models Towards Therapeutic Significance DJ Mc Carthy, M Malhotra, AM O’Mahony, JF Cryan, CM O’Driscoll Pharmaceutical research 32, 1161-1185, 2015 | 137 | 2015 |
| Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice ODCM Guo J., Ogier J., Desgranges S., Darcy R. Biomaterials 33, 7775-7784, 2012 | 137 | 2012 |
| Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate BT Griffin, M Kuentz, M Vertzoni, ES Kostewicz, Y Fei, W Faisal, C Stillhart, ... European Journal of Pharmaceutics and Biopharmaceutics 86 (3), 427-437, 2014 | 134 | 2014 |
| Self-assembling modified β-cyclodextrin nanoparticles as neuronal siRNA delivery vectors: Focus on Huntington’s disease BMDC Godinho, JR Ogier, R Darcy, CM O’Driscoll, JF Cryan Molecular pharmaceutics 10 (2), 640-649, 2013 | 133 | 2013 |
| Therapeutic targeting in the silent era: advances in non-viral siRNA delivery J Guo, KA Fisher, R Darcy, JF Cryan, C O’Driscoll Molecular Biosystems 6 (7), 1143-1161, 2010 | 133 | 2010 |
| The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics KA Fitzgerald, J Guo, EG Tierney, CM Curtin, M Malhotra, R Darcy, ... Biomaterials 66, 53-66, 2015 | 123 | 2015 |
| Evaluation of Cellular Uptake and Gene Transfer Efficiency of Pegylated Poly-l-lysine Compacted DNA: Implications for Cancer Gene Therapy M Walsh, M Tangney, MJ O'neill, JO Larkin, DM Soden, SL McKenna, ... Molecular pharmaceutics 3 (6), 644-653, 2006 | 114 | 2006 |
| The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease JC Evans, M Malhotra, JF Cryan, CM O'Driscoll British journal of pharmacology 173 (21), 3041-3079, 2016 | 110 | 2016 |
Jianfeng GuoSchool of Pharmaceutical Sciences, Jilin University在 jlu.edu.cn 的电子邮件经过验证
